Skip to content

Pilot Feasibility Trial of the SafeLM Supraglottic Airway (SGA)

Pilot Feasibility Trial of the SafeLM Supraglottic Airway

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05989880
Enrollment
60
Registered
2023-08-14
Start date
2023-09-19
Completion date
2025-12-02
Last updated
2024-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Brief summary

The purpose of this study is to assess the feasibility of SafeLM as a primary airway device and as a conduit for intubation with and without the use of a bougie

Interventions

DEVICESafeLM as a supraglottic airway device with video capability

The device will be inserted using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.

DEVICESafeLM as a supraglottic airway device without video capability

The device will be blindly inserted without using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The video capability of the device will be used to assess the accuracy of placement after the fact. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.

DEVICESafeLM as a conduit for intubation using an endotracheal tube with video capability

The device will be inserted, and an endotracheal tube will be advanced through the device under direct visualization using the video capability of the device. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The endotracheal tube will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device. The endotracheal tube will be advanced into the trachea, and the position will be confirmed by end-tidal carbon dioxide (EtCO2) detection and chest auscultation. The cuff of the endotracheal tube will be inflated, and mechanical ventilation will be resumed. The SafeLM device will be removed, and the position of the endotracheal tube will be confirmed once again.

DEVICESafeLM as a conduit for intubation using a bougie with video capability

The device will be inserted. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening.The position of the device will be confirmed by observing the video image of the glottis on the monitor. The video camera on the SafeLM will be turned on to visualize the vocal cords.A standard airway bougie will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device.The SafeLM device will be removed, and an appropriately sized endotracheal tube will be advanced into the trachea. If a bougie is not able to be inserted into the tracheal under direct visualization, direct insertion of an endotracheal tube into the trachea will be attempted, followed by flexible scope intubation.

Sponsors

The University of Texas Health Science Center, Houston
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* elective surgery requiring general anesthesia and airway management using a supraglottic airway device or endotracheal intubation

Exclusion criteria

* pregnancy * known or suspected difficult airway management * history of oropharyngeal or upper airway surgery * known or suspected airway or respiratory pathology, such as significant obstructive sleep apnea or chronic obstructive pulmonary disease (COPD) * BMI greater than 40 kg/m2 * unable to undergo intubation via the oral route * known or suspected full stomach or other risk factors for aspiration * contraindication for the use of neuromuscular blocking agents * history of significant gastroesophageal reflux disease (GERD) * Vulnerable populations (cognitively impaired persons, prisoners)

Design outcomes

Primary

MeasureTime frameDescription
Intubation success rateat the time of intubationThis is assessed by the ability of the SafeLM to achieve adequate oxygenation and ventilation via the respective procedure once the airway device is in place.

Secondary

MeasureTime frameDescription
Number of insertion attempts required to achieve effective oxygenation and ventilationat the time of intubation
Time to insertionat the time of intubationThis is measured by the time from opening the mouth to the time of end tidal CO2 on capnography
Subjective ease of insertion of the airway deviceat the time of intubation
Safety of the SafeLM as an SGAat the time of intubationThis will be assessed by the number of adverse events such as airway obstruction, aspiration, and hypoxia.
Safety of the SafeLM as a conduit for intubationat the time of intubationThis will be assessed by the number of adverse events such as esophageal intubation, bronchial intubation, and hypoxia during the intubation process.

Countries

United States

Contacts

Primary ContactLauren M Nakazawa, MD
Lauren.M.Nakazawa@uth.tmc.edu713-500-6775
Backup ContactCarlos Artime, MD
Carlos.Artime@uth.tmc.edu713-500-6171

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026